We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

CCL:NYSECarnival Corporation Analysis

Data as of 2026-05-24 - not real-time

$25.98

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Carnival Corp. (CCL) has rallied ~9% on the completion of its dual‑listing unification and redomiciliation, a material corporate event that cleared structural uncertainty and sparked short‑term buying pressure. The stock now trades just above its 20‑day SMA (≈$25.8) but remains below the 50‑day and 200‑day averages, while the MACD line has crossed above its signal, signaling a nascent bullish momentum despite a broader bearish trend. Technical indicators such as a neutral RSI (≈50) and a support level near $23.45 suggest limited downside, and the price sits comfortably below the analyst median target of $34, implying roughly 30% upside potential.
Fundamentally, CCL delivers solid profitability with a 55% gross margin, 9.8% operating margin, and a robust ROE of 27.9%. However, the balance sheet is heavily leveraged (debt‑to‑equity >200%) and the DCF‑derived fair value (~$8.3) is far below the market price, flagging valuation caution. The dividend remains modest at 1.15% with a low payout ratio (~6.6%), indicating sustainability as long as free cash flow stays positive.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Recent corporate unification and redomiciliation boosting sentiment
  • Bullish MACD crossover and price above short‑term SMA
  • Support level intact with limited downside risk

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Analyst median target price of $34 indicating ~30% upside
  • Strong operating margins and high ROE supporting earnings growth
  • Sustainable dividend and positive free cash flow

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • High leverage (debt‑to‑equity >200%) poses balance‑sheet risk
  • Cyclical nature of cruise travel and exposure to regulatory changes
  • Long‑term brand strength and diversified geographic footprint

Key Metrics & Analysis

Financial Health

Revenue Growth6.10%
Profit Margin11.48%
P/E Ratio11.4
ROE27.85%
ROA5.52%
Debt/Equity203.90
P/B Ratio2.8
Op. Cash Flow$6.6B
Free Cash Flow$2.2B

Technical Analysis

TrendBearish
RSI49.8
Support$23.45
Resistance$28.05
MA 20$25.82
MA 50$26.11
MA 200$28.56
MACDBullish
VolumeDecreasing
Fear & Greed Index91.61

Valuation

Fair Value$8.32
Target Price$34.01
Upside/Downside30.91%
GradeFair
TypeBlend
Dividend Yield1.15%

Risk Assessment

Beta2.28
Volatility54.16%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.